Predictive Oncology Announces New Chief Executive Officer Raymond F. Vennare to Lead Company Growth
October 20 2022 - 8:30AM
Predictive Oncology (NASDAQ: POAI) is pleased to announce the
appointment of Raymond F. Vennare as Chief Executive Officer and
Chairman of the Board, effective Nov. 1.
As an active member on the POAI Board of Directors since
September 2021 and, as an accomplished senior executive with more
than three decades of experience building biotechnology and
bioinformatics companies across diverse markets in life sciences,
Mr. Vennare emerged as a clear frontrunner to serve as the next
Chief Executive Officer of Predictive Oncology.
“We are fortunate to have Raymond leading Predictive Oncology at
this pivotal time in our company’s evolution. He is an experienced
biotechnology executive who brings an informed vision and fresh
perspective to our company as we strive to become a significant
player in the pharmaceutical and biotech industries. He has the
right balance of entrepreneurship, innovation, technology
commercialization and strategic thinking that makes him the right
fit to grow our business,” shared Bob Myers, Chief Financial
Officer of Predictive Oncology.
Mr. Vennare will continue to work closely with the company’s
senior management to expand its portfolio of proprietary solutions
to advance the pipeline of drug development in oncology, ranging
from early discovery through clinical trials. He will lead
Predictive Oncology’s efforts to evolve the company’s core products
and services, which include its flagship technology that pairs
artificial intelligence with the world’s largest commercial biobank
for oncology drug discovery, as well as the application of 3D tumor
models and formulation solutions.
“Having served on the Board of Directors of Predictive Oncology
for more than a year, now, I have come to recognize the unmet needs
in the marketplace, the growth potential for the company and the
passion of the people who will make this all happen,” said Mr.
Vennare. “What we do for our customers today, will directly impact
the lives of those patients who may benefit by these discoveries,
in the future.”
An accomplished senior executive and biotechnology entrepreneur,
Mr. Vennare has a long history of founding, advising and leading
companies in both the private and public sectors, ranging from
bioinformatics, diagnostics and therapeutic drug delivery to
FDA-cleared medical devices. He has played a key role in company
formation, capitalization, business development and execution of
commercialization opportunities for novel technologies.
Since 2015, Mr. Vennare has served as CEO and Chairman of
Cvergenx, Inc., a genomic informatics company developing
decision-support tools for radiation oncology, and is currently an
Investment Partner in Inventeur, LLC, a holding company of medical
technologies in anesthesiology. Mr. Vennare’s previous experience
includes co-founding ThermalTherapeutic Systems, Inc., where he
served as President and Chief Executive Officer, President and
Chief Executive Officer of ImmunoSite, Inc., Senior Vice President
and Chief Information Officer of TissueInformatics, Inc., and
President of VS/Interactive.
Mr. Vennare earned his undergraduate degree from the University
of Pittsburgh and holds graduate degrees from Duquesne University
and Case Western Reserve University, and a non-degree Certificate
in Technology Commercialization from Carnegie Mellon
University.
About Predictive OncologyPredictive Oncology
(NASDAQ: POAI) is a knowledge-driven company focused on applying
artificial intelligence (AI) to develop optimal cancer therapies,
which can lead to more effective treatments and improved patient
outcomes. Through AI, Predictive Oncology uses a biobank of
150,000+ cancer tumors, categorized by patient type, against drug
compounds to help the drug discovery process and increase the
probability of success. The company offers a suite of
solutions for oncology drug development from early discovery to
clinical trials.
Public Relations Contact:Predictive
OncologyTheresa Ferguson(630)
566-2003tferguson@predictive-oncology.com
Investor Relations Contact:Landon Capital Keith
Pinder(404) 995-6671kpinder@landoncapital.net
Forward-Looking Statements:Certain matters
discussed in this release contain forward-looking statements. These
forward-looking statements reflect our current expectations and
projections about future events and are subject to substantial
risks, uncertainties and assumptions about our operations and the
investments we make. All statements, other than statements of
historical facts, included in this press release regarding our
strategy, future operations, future financial position, future
revenue and financial performance, projected costs, prospects,
changes in management, plans and objectives of management are
forward-looking statements. The words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Our actual future performance may
materially differ from that contemplated by the forward-looking
statements as a result of a variety of factors including, among
other things, factors discussed under the heading “Risk Factors” in
our filings with the SEC. Except as expressly required by law,
the Company disclaims any intent or obligation to update these
forward-looking statements.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/bb245662-d0b3-4386-b9a9-04daf09d038d
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024